RARE / dtx301-otc-deficiency — DTX301 (avalotcagene ontaparvovec) for late-onset ornithine transcarbamylase (OTC) deficiency

Program analysis · bpiq_drug_id 17190 · prepared 2026-08 · USD · framework v5.6.1 · Coverage: CLEARED

Company context, financials, ownership, options and the full pipeline: ../company.md.

How to read this. Written for a reader who has not studied pharmacology or finance. Terms specific to this program are in the Glossary below; general terms are defined once in framework/04-glossary.md. Tags: [VERIFIED — source] / [UNVERIFIED] / [WEB ESTIMATE — source, date].

This document supersedes the v3.7.0 analysis of 2026-08-05. The prediction it locks supersedes RARE-17190-2026-08-05.

Row resolution. fetch_company_drugs for RARE returned nine rows on 2026-08-12, every one of them listed in ../company.md C.2. This document analyses row id 17190: drug_name “DTX301 ” (with a trailing space), indications_text “Ornithine transcarbmylase deficiency” (the source’s own misspelling), stage_event_label “Phase 3 Data readout”, catalyst_date 2027-06-30, catalyst_date_text “H1 2027”, has_catalyst true. It is the only row matching this molecule; the name was not used to resolve it, the integer id was. The other eight rows: 18004 UX111 (PDUFA 2026-09-19, has_catalyst true), 17189 DTX401 (PDUFA 2026-08-23, true), 17188 GTX-102 (Phase 3 readout H2 2026, true), 17191 UX701 (Phase 1/2 readout “2026”, true), 17187 UX143 setrusumab (failed, false), 17192 UX053 (TBA, false), 20225 and 20222 UX016 (duplicate rows, Phase 1/2 initiation H2 2026, false).

Glossary

Executive summary

• What it is (one sentence): A one-time intravenous gene therapy that puts a working copy of the OTC gene into liver cells, so that people with a mild inherited urea-cycle disease can control blood ammonia without lifelong scavenger drugs and a protein-restricted diet.
• The event and when (as disclosed): The 64-week follow-up data from the Phase 3 Enh3ance study, guided to “H1 2027” — a six-month window, not a day, now stated three times without change (2026-03-12, 2026-05-05, 2026-08-04). This is the trial’s second primary endpoint. The first primary endpoint already read out positive on 2026-03-12.
• The main reason it could work: The hard part is already done. At Week 36 the trial hit its first primary endpoint with an 18% reduction in 24-hour plasma ammonia against placebo at p=0.018, and eight of nine patients who had abnormal ammonia at baseline despite optimal drug and diet were pushed into the normal range. The 64-week endpoint asks the same patients a follow-on question, and the Week 36 secondary data — a 27% mean cut in scavenger medication and a 13% rise in protein intake — already point the right way.
• The main risk: The 64-week endpoint is a binary one. “Complete responder” means off scavengers and off protein restriction, not merely on less of both. A 27% mean reduction at Week 36 is a long way from zero, and the tapering decision rests with treating physicians who have every reason to be cautious with a disease that kills through crises. There is no published success threshold for the endpoint, which also makes it harder to settle cleanly.
• What it means for the stock: Very little, and that is the finding. On 2026-03-12 this exact trial reported a statistically significant win on its first primary endpoint and the shares fell 1.0% on the day. The attribution computation now confirms what the prose said last time: three sibling catalysts with disclosed dates — two PDUFA decisions and the Angelman readout — land within six months of this program’s window, so no move around it can be read as this program’s alone. The stock call is no-edge.

0. Program-tier coverage — CLEARED

Company-tier coverage is in ../company.md C.0 and is not repeated here. The company tier was swept 2026-08-07 and is reused under 02-connectors.md § Company-sweep currency: within 30 days, and the press feed to 2026-08-12 carries no intervening earnings release or financing (the new items since 2026-08-07 are rating notes, Schedule 13G updates, an institutional sale and a 2026-08-11 DOJOLVI generic-litigation settlement licensing Esjay from 2033).

No mandatory program-tier row reads NOT CALLED, so this program clears the gate. One row is BLOCKED; the claim it would have supported is tagged [UNVERIFIED] rather than asserted, and the block is named where it bites.

A. Scientific & clinical assessment

A.1 Mechanism of action and scientific rationale

The body breaks protein down into ammonia. Ammonia is poisonous to the brain, so the liver runs a five-step chemical assembly line called the urea cycle that converts it into urea, which the kidneys pass out in urine. Ornithine transcarbamylase (OTC) is the enzyme that performs the second step. If the gene for it is faulty, the assembly line stalls and ammonia builds up in the blood. According to PubMed, the disease and its neurological burden are reviewed in Metabolic Brain Disease [VERIFIED — PubMed, DOI 10.1007/s11011-026-01812-0, metadata re-retrieved 2026-08-12].

Because the OTC gene sits on the X chromosome, males — who have only one copy — are usually affected more severely. The severe form appears within days of birth. The late-onset form, which is the population DTX301 treats, leaves enough residual enzyme that patients get through infancy and present later, sometimes as adults, with episodes of confusion, vomiting or seizures that are frequently mistaken for something else [VERIFIED — same review]. Standard care is not a treatment for the cause. It is ammonia scavenger drugs taken several times daily for life, plus a protein-restricted diet, and the two together are the burden the patient actually lives with.

What DTX301 does. It is a single intravenous infusion of a modified adeno-associated virus serotype 8 (AAV8) carrying a working copy of the human OTC gene. AAV8 naturally homes to liver cells. Once inside, the delivered gene sits in the nucleus as a free loop of DNA — episomally, without being spliced into the patient’s own chromosomes — and the cell reads it and starts making working OTC enzyme [VERIFIED — ChEMBL CHEMBL4650252 records the molecule as molecule_type “Gene” with synonym “Scaav8otc”, called 2026-08-12; mechanism described in the Ultragenyx 2026-03-12 release]. Because the gene is episomal, it is diluted away every time a liver cell divides. That is why liver gene therapy is more durable in adults than in growing children, and it is a live question for how long a single dose lasts.

How well the target is validated. As well as any target in medicine, in the ordinary sense that the causal chain is completely understood: a specific enzyme is missing, the consequence is measurable in the blood, and supplying the enzyme’s gene fixes the measurement — demonstrated in this program’s own randomised Phase 3 at p=0.018. The independent-platform corroboration could not be re-run this session: Open Targets search_entities returned the verbatim Rate limit exceeded for client: global on all four attempts, so the platform’s gene–disease assertion is cited from the 2026-08-05 sweep (OTC → ENSG00000036473, OTCD → MONDO_0010703) rather than re-verified, and this session’s state is [UNVERIFIED — Open Targets BLOCKED 2026-08-12]. The limit of that check is unchanged: for a monogenic enzyme deficiency the causality is not in dispute, and the association’s numeric evidence score has never been retrieved in either sweep.

The exact scientific step the next readout must prove. Not that the drug lowers ammonia — that is settled. It must prove that lowering ammonia is enough for patients to come off the scavenger drugs and off the protein-restricted diet and stay well. The trial calls that a complete responder, and the complete responder rate through 64 weeks is its second primary endpoint [VERIFIED — ClinicalTrials.gov NCT05345171, get_trial_details 2026-08-12].

The honest scientific risk. Three things.

1. Enzyme replacement is graded, not binary. A partial restoration of OTC activity lowers ammonia without necessarily giving enough headroom to abandon both safety nets. The Week 36 secondary data are consistent with exactly this: scavenger use fell 27% on average and protein intake rose about 13%, which is real improvement and is not discontinuation.
2. The immune system fights the vector. AAV liver gene therapy provokes hepatic inflammation and a T-cell response to the capsid, which is why the protocol includes a corticosteroid regimen. One treatment-related acute hepatitis occurred in the DTX301 arm and resolved with steroids. If steroids fail to protect the transduced cells, expression falls and a Week 36 responder can stop being one by Week 64.
3. Durability is unproven at this timescale in this trial. Episomal DNA does not replicate. The Phase 1/2 long-term follow-up study NCT03636438 exists precisely to answer this and runs to 2029-12; it has 11 participants.

A.2 Clinical development plan, timeline, feasibility, resourcing

Trials

Feasibility matrix

Resourcing sufficiency. Yes, comfortably, for this program. The trial is fully enrolled and dosed; the incremental cost to the Week 64 readout is follow-up visits and analysis, not manufacturing or recruitment. The company’s cash runs to roughly August 2027 on recomputed burn (see ../company.md C.3), which covers the guided H1 2027 readout — though only just if the readout lands late in the window, and the runway question there is a company-level question about the next financing, not about whether this readout happens. Two saleable priority review vouchers (if the August and September approvals land) and growing product revenue are the company’s stated cushions.

A.3 Target label, target product profile, strategic questions, designations

A.3a Target label. A single intravenous dose for the treatment of adults and adolescents aged 12 and over with late-onset ornithine transcarbamylase deficiency, to maintain safe plasma ammonia and reduce or remove the need for ammonia scavenger drugs and protein restriction.

A.3b Target product profile

A.3c Strategic Go/No-Go questions. The asset’s next decision is a registration filing, so the pre-Phase-III / registration set is the one that applies.

A.3d Regulatory designations.

• Orphan drug designation, United States and European Union. It grants seven years of United States market exclusivity from approval for the designated indication, ten years in the European Union, plus fee waivers and protocol assistance. [VERIFIED — Ultragenyx's own "About DTX301" boilerplate in the 2026-03-12 release, re-read 2026-08-12]
• Fast Track designation, United States. It grants more frequent FDA interaction, and eligibility for rolling review of a filing and — if criteria are met — priority review. This corrects the previous version of this analysis, which reported that no Fast Track designation had been found: the company’s own release boilerplate states “Orphan Drug Designation in the United States and EU and Fast Track Designation in the United States.” The designation is stated by the sponsor; no FDA-side confirmation was pulled. [VERIFIED — Ultragenyx 2026-03-12 release boilerplate, read via StockTitan rendering 2026-08-12]
• No Breakthrough Therapy, RMAT or priority-review designation for DTX301 was found. Sibling assets DTX401 (priority review) and UX111 and GTX-102 (Breakthrough Therapy) do carry stronger designations, so the absence of those here remains informative. [VERIFIED — BPIQ press feed, 414 items, scanned 2026-08-12]

A.4 Target product profile valuation matrix

A.5 Evidence quality and endpoints

Endpoints

A.5b Key opinion leaders.

Panel as of. 2026-08-12. The panel below is thin, and its thinness is the recorded finding rather than a gap left silent.

Investigators

No investigator rows could be recorded. ClinicalTrials.gov lists no overall officials and no investigator or contact names for NCT05345171 — all sixteen site rows carry facility and address only — and CT.gov search_investigators over ornithine transcarbamylase deficiency trials (30 trials analysed, 65 names returned, 2026-08-12) returned no name attached to this NCT. The names it did return for this disease belong to the competitor’s trial (iECURE’s NCT06255782) and to an NIH hyperammonaemia biomarker study. An empty table over a fully-enrolled pivotal trial is a registry-disclosure artifact, not evidence that the trial has no investigators; the sixteen named academic centres in A.2 are the closest available proxy.

Independent voices

No independent voice could be recorded. The only named clinical commentary on this program’s endpoint found in either sweep is the Metabolic Brain Disease disease review, whose author panel (Konczal — University Hospitals Cleveland, an Enh3ance site; Enns — Stanford; Gropman — St. Jude; Wilkening — Colorado, another Enh3ance site) includes two Ultragenyx employees as co-authors (Garcia, Merritt) [VERIFIED — PubMed, DOI 10.1007/s11011-026-01812-0, author affiliations, 2026-08-12], so none of its clinician authors can be held out as independent of the sponsor, and a trade-press piece (NeurologyLive, 2026-03) could not be re-opened this session (HTTP 403). In an ultra-rare disease whose trial sites are the field’s main academic centres, genuinely independent expert commentary may simply not exist — which is itself worth knowing.

Judgement

Dissent

B. Commercial assessment

B.0 Current treatment algorithm

What a patient with late-onset OTC deficiency receives today, in order:

1. Diagnosis, often late and often after an emergency-department presentation for confusion, vomiting or seizures. Confirmed by enzyme assay on liver biopsy, by a biochemical pattern (high ammonia with high glutamine, low citrulline, high urinary orotic acid) or by molecular OTC testing. Diagnostic delay is the field’s own stated problem [VERIFIED — PubMed, DOI 10.1007/s11011-026-01812-0].
2. Protein-restricted diet, for life, with essential amino acid supplementation. Restrictive and hard to sustain.
3. Ammonia scavenger drugs — glycerol phenylbutyrate, sodium phenylbutyrate or sodium benzoate — several times daily, for life. They give nitrogen a second exit route. They work and they are unpleasant.
4. Emergency management of hyperammonaemic crises: hospitalisation, intravenous scavengers, sometimes dialysis. This is where the deaths happen.
5. Liver transplant, the only curative option today. It works, and it costs an operation, a donor organ and lifelong immunosuppression.

Where DTX301 fits. At step 2–3, replacing them. It is the first therapy that would address the cause rather than route around it, short of transplant. It does not open a new line of therapy; it removes two existing ones. It creates no new patient pool — the patients already exist and are already treated.

B.1 Competitive landscape and positioning

Where this asset wins, in plain sentences. It wins on being years ahead in the population it targets, on being a single infusion against a lifetime of thrice-daily drugs, and on having already produced a statistically significant randomised result — which nobody else in urea cycle gene therapy has. It does not win on size: this is an ultra-rare disease and the late-onset subset of it is smaller still.

The single fact the thesis rests on. That a graded improvement in enzyme activity is enough for patients to be taken off both scavengers and protein restriction, not merely put on less of them. Everything commercial about a one-time gene therapy — the price, the payer argument, the differentiation from a cheap generic scavenger — depends on that binary.

B.2 Addressable market

Launch markets would be the United States, the European Union, and the countries where Enh3ance ran: Argentina, Brazil, Canada, France, Germany, Japan, the Netherlands, Portugal and Spain.

B.3 Value and feasibility

B.3a Expected peak sales. Built bottom-up: eligible patients × one-time price × penetration. This is a one-time therapy, so “peak sales” means the annual revenue in the years when the prevalent backlog of diagnosed patients is being treated, and it declines toward the incidence rate afterwards. That decay is a feature of gene therapy economics and is stated rather than buried. All three scenarios are conditional on approval, assume a first launch no earlier than 2028, and exclude any European or Japanese pricing differential, any priority review voucher, and any value from the platform. They are unchanged from the 2026-08-05 analysis because no input changed: the company’s ~10,000-patient figure is consistent with the patient-pool arithmetic already used.

What is not passed through. Market-research aggregators put the whole “OTC deficiency treatment market” at $0.69–0.85 billion today rising to $1.0–1.08 billion by 2031–2035, with roughly $0.33 billion by 2031 attributable to gene replacement [WEB ESTIMATE — Mordor Intelligence, GMInsights, Verified Market Research and others, read 2026-08-05]. Those figures are not used as inputs. They aggregate several vendors’ incompatible definitions, they include existing scavenger sales, and their patient-count basis contradicts itself five-fold. The $0.33 billion gene-therapy line is roughly consistent with the base case above, which is noted as a coincidence rather than as corroboration.

B.3b Feasibility

B.4 Product-development risk

Framing questions.

1. Does the development plan support the target product profile claims? Partly. The plan proves ammonia control — and has already done so. The target product profile’s central claim is freedom from scavengers and protein restriction, and the endpoint that tests it is the one that has not read out yet and has no published success bar.
2. Will the identified risks affect the target product profile? Yes, one of them decisively. If the complete responder rate is low, the label becomes “reduces ammonia and reduces scavenger burden” rather than “replaces treatment”, and the price a payer will accept for a one-time therapy falls with it.
3. If a risk cannot be mitigated, is the asset still differentiated from competitors? Yes. Even a partial result leaves DTX301 the only randomised, statistically significant, Phase 3 result in urea-cycle gene therapy, years ahead of ECUR-506, in a disease with no approved disease-modifying option.

Readout

Sources

The modelled estimate. CT.gov primary_completion_date 2027-09 plus the 01-rules.md rule 34 default lag of two to four months to database lock and analysis: 2027-09 + 2 months = 2027-11; 2027-09 + 4 months = 2028-01. The caveat that matters: the registry field very likely tracks the last crossover patient’s final study visit rather than the Week 64 dataset the company will actually analyse — enrolment completed 2025-02, so the last originally-randomised patient’s Week 64 and the crossover cohort’s 64-weeks-post-infusion visits complete in roughly early 2027, which is consistent with the company’s H1 2027 guidance. That reconciliation is an [UNVERIFIED] inference, which is exactly why the modelled row above is reported at face value rather than adjusted to fit it.

Window

Basis. The earliest edge is the opening of the guided half-year, stated three times without change by a sponsor whose last guidance for this same trial (the Week 36 readout) was delivered on schedule. The likeliest date sits late in the guided half because the crossover arithmetic puts the last 64-week visits in early-to-mid 2027 and analysis follows them, and because a sponsor guiding a half tends to land in its back part. The latest edge extends past the guided half to the registry’s own primary completion month-end (2027-09-30), because the plainer reading of that field — that the readout can slip into H2 2027 — is not excluded; the full modelled top (2028-01) is not adopted as the edge because the endpoint’s own 64-week clock most plausibly completes well before the registry date, but the UNRESOLVED disagreement below is the honest record that it could run later. Precision is PERIOD: no source names a month or a day. Confidence is MEDIUM rather than HIGH because the two independent sources genuinely disagree, and rather than LOW because the guidance is dated, thrice-repeated, and mechanically plausible against a fully-enrolled trial with all dosing done.

Disagreement. UNRESOLVED. The company guides H1 2027 (three dated statements). The registry’s primary completion is 2027-09, a quarter after the guided window closes, and the rule 34 modelled estimate built on it lands 2027-11 to 2028-01, wholly after the guided half. Neither side is picked and they are not averaged (rule 24); the window above leans on the company’s dated guidance for its open and stretches its close to the registry’s own month.

Date slippage. Zero slips across three dated statements — and a zero-slip record spanning five months is stronger than the two-statement record the previous analysis called “merely young”, though still short of the multi-year clean records elsewhere in this corpus. One caveat: the BPIQ note field now carries only the latest entry rather than the dated changelog it carried at the 2026-08-05 sweep, so the first two rows below are carried from that sweep’s own verified reading of the then-fuller field.

Attribution

Status. CONTAMINATED

Computed by lib/clustering.mjs’s attributionFor over this ticker’s full pipeline (every has_catalyst: true row, analysed or not) with this program’s own readout window above, 2026-08-12. Transcribed, not estimated.

Conflicts

Note. Three of the four conflicts are confirmed on disclosed dates: the DTX401 PDUFA (2026-08-23, exact) and the UX111 PDUFA (2026-09-19, exact) land 131 and 104 days before this program’s window opens, and GTX-102’s MONTH-precision ASPIRE window closes 52 days before it. Neither PDUFA program has a document of its own — only the pipeline table carries them, which is what this computation exists to catch. The consequence for this program is about the baseline, not simultaneous news: the price level the shares hold when the H1 2027 window opens will have been set by three larger events in the preceding four months, so no scenario range or move around this program’s readout can be attributed to DTX301 alone, and the stock call below is written under that constraint. The fourth conflict (UX701, gap 1 day) is two period placeholders touching and confirms nothing.

Market and timing for this event

Company-level figures — price, market capitalisation, the 52-week range, ownership and the options chain — live in ../company.md and are cited by section rather than restated.

• Plain takeaway. The market has already been shown this program’s best card and did not clap. On 2026-03-12 the identical trial reported a statistically significant win on its first primary endpoint and the shares closed down 1.0%. Nothing in the intervening five months has changed that read, and before this program’s window opens the equity will have been repriced by the two 2026 approval decisions and the Angelman readout — the attribution block above now states that as a computed finding rather than prose.
• Months to this catalyst. 4.7 to 13.6 months from 2026-08-12, reading readout.window above (earliest 2027-01-01, latest 2027-09-30) — never catalyst_date (rule 23). The precision is PERIOD: “H1 2027” is a six-month disclosure, not a date.
• Expected move around this event. Not readable from the chain. The options chain in ../company.md C.6 has eight expiries and the last one before H1 2027 ends is 2027-02-19; the next is 2028-01-21. No listed expiry brackets a mid-2027 event. The honest answer remains a bracket built from this ticker’s own reaction function rather than from the chain: 0% to −15% on a positive result and −5% to −25% on a miss, from C.7.
• Nearest comparable past reaction. ../company.md C.7, the 2026-03-12 row: DTX301 Phase 3 Enh3ance Week 36 primary endpoint met at p=0.018, shares −1.00% intraday on a −1.26% gap, with nothing else in the same-day press feed. It is comparable in almost every respect that matters — same drug, same trial, same disease, same kind of endpoint, clean attribution — and that is exactly why it is the anchor. It is not comparable in one respect: the Week 36 result was the first randomised evidence and the Week 64 result will land alongside a filing decision, which could give it slightly more weight.
• Materiality. Meaningful, not dominant, as recorded in ../company.md C.2. The first primary endpoint is already banked; this is the second, in an ultra-rare indication, at a company with $730–760M of guided revenue and a recomputed enterprise value of at least $2,203M. The no-edge stock call below is consistent with that materiality (rule 27).
• Date slippage. Zero slips across three dated statements — see Readout above.

Spot. $26.67, the latest BPIQ-quoted price read 2026-08-12 (previous close $26.96 on 2026-08-11). The committed price cache ends 2026-08-05 at $24.93; both are recorded with their own dates and the fresher quote is the one the scenarios are measured against. Company-level valuation context is in ../company.md C.4, whose own spot ($25.82) is the 2026-08-06 close from the reused 2026-08-07 sweep.

Scenario prices

The event is roughly five to thirteen months away, so the absolute level the shares trade at in H1 2027 will be set overwhelmingly by the DTX401 and UX111 approval decisions and by the Angelman readout, none of which is this program — the attribution block above is the computed statement of the same fact. The ranges below are honest about that: they are narrow, they straddle spot, and the DTX301-attributable component of each is small.

Expected value. Applying the 62% modelled probability to the midpoint of each range — $30.00 positive, $24.50 miss — gives $27.91, which is +4.6% against the $26.67 spot. This is arithmetic, not advice, and it is not a price target. A +4.6% expected value five-to-thirteen months out is inside any reasonable noise band, which is precisely why the direction call below is no-edge.

Run-up

Rule 39 does not withhold this call — readout.precision is PERIOD, not UNKNOWN — but the date-confidence gate prices its coarseness: the priority score below is capped by the formula’s untradeable ceiling, which is the mechanism telling a reader this run-up is close to untradeable without anyone having to remember the caveat.

Entry and exit

The exit the rule resolves to is a later fact: the committed price cache ends 2026-08-05, well before the window opens, so lib/runup.mjs’s resolveExit returns null today and exit is recorded as null on the prediction.

Predicted move and peak

Priority score drivers

The five computed rows are transcribed from lib/runup.mjs’s scoreDriver output, 2026-08-12.

Priority score. Priority score 8 · formula_version 1.0.0

The arithmetic is worth one sentence: the weighted base lands near 39, the PERIOD×MEDIUM gate multiplies it by 0.20, and the financing-and-clustering driver at 100 contributes zero safety — this is among the least attractive run-up setups the formula can describe short of an UNKNOWN window, and that is the correct reading of a coarse-dated, heavily-contaminated, low-materiality event.

Settlement. Left null at lock time, per 05-prediction-protocol.md § Run-up settlement.

Verdict

What I would do. Watch — and watch it as a company story, not as this program’s story.

Why. The science here is in good shape and the trade is not. The first primary endpoint is already met, the mechanism is textbook, the trial is fully enrolled with zero date slips across three dated statements, and the placebo arm produced five crisis hospitalisations and a death against one crisis and no deaths on drug, which is about as clean a benefit/risk picture as an ultra-rare trial produces. But the market has already run the experiment on how it prices this program: on 2026-03-12 the same trial reported a significant win and the shares fell 1%. Before this program’s window opens, the equity will have been set by two approval decisions and the Angelman readout — the attribution computation now records that as three confirmed conflicts rather than a caveat sentence. There is a real scientific question in the Week 64 endpoint — graded improvement versus a binary bar, with no published threshold — and it is worth following on the merits. It is not worth positioning for.

What would change this. Upward: disclosure, at any point before the readout, of the complete responder rate observed so far in the crossover patients, or a pre-specified success threshold for the endpoint appearing in a protocol amendment or a filing. Either would convert an unscoreable judgement into an arithmetic test and would move the probability materially in whichever direction it pointed. Downward: a hepatic safety event in the crossover cohort, or a movement of the ClinicalTrials.gov primary completion date later than 2027-09, which would mean the guided window has broken.

What to watch.

• 2026-08-23 — the DTX401 approval decision, eleven days away. Same company, same AAV platform, same manufacturing site. It is the first external verdict on whether Ultragenyx’s gene-therapy chemistry, manufacturing and controls satisfy the FDA, and a Complete Response Letter there would read across directly to DTX301’s eventual filing.
• 2026-09-19 — the UX111 approval decision, which already carries one Complete Response Letter on manufacturing observations. Same read-across, sharper.
• September or October 2026 — the ASPIRE Angelman topline. It will set the price level against which this program’s H1 2027 event is eventually measured.
• Any date — the appearance of a peer-reviewed publication of DTX301 human data. There is none today, which is the weakest point in the evidence base (A.5), and nothing has appeared since the previous sweep.
• The Q3 2026 release (~2026-11) — whether “H1 2027” is stated a fourth time unchanged. Three reiterations make the zero-slip record meaningful; a fourth makes it strong.
• 2027-09 — the ClinicalTrials.gov primary completion date for NCT05345171. If it moves later, the guided window has broken. It did not move between 2026-08-05 and 2026-08-12.

Locked prediction

• Outcome-direction (will the readout succeed on its primary endpoint?): positive — probability 62%, band 48–75% [UNVERIFIED — modelled]. The reasoning is unchanged from the superseded record because the evidence base is unchanged: the pharmacology is already demonstrated in this exact trial at p=0.018, the Week 36 treatment-burden secondaries move the right way (−27% scavengers, +13% protein), and the crossover adds nineteen more exposed patients to the denominator by Week 64. Against that, the endpoint is binary where the evidence so far is graded, a 27% mean scavenger reduction is a long way from discontinuation, and physicians tapering therapy in a disease that kills through crises will be cautious. The band spans 50 deliberately: no published success threshold for the complete responder rate could be found in either sweep, so part of the uncertainty is about how “met” will be judged rather than about the biology. No third-party published probability for this specific endpoint was found.
• Stock-direction (which way do the shares move?): no-edge — confidence low — window 2027-01-01 to 2027-10-31, basis: readout.window above (earliest 2027-01-01, latest 2027-09-30, the registry’s own primary completion month) plus four weeks for the market to digest a print that could land on the window’s last day. The call is no-edge because ../company.md C.2 records this program as meaningful, not dominant, and because C.7 records that the identical trial’s first primary-endpoint win moved the shares −1.0%. Attribution is CONTAMINATED: the DTX401 and UX111 PDUFAs and the ASPIRE window all sit within six months of this window’s open on disclosed dates, so the level and direction of the shares around this event cannot be attributed to it alone. The +4.6% expected value is not a contradiction of no-edge: it is small, it sits well inside the dispersion the two ranges imply, and essentially all of it is other programs’ repricing.
• Scenario prices: positive $27–$33 · miss $22–$27
• Expected value: $27.91, +4.6% against spot $26.67 (arithmetic, not advice)
• Run-up: entry $26.67 on 2026-08-12, exit rule T-5 trading days before readout.window.earliest — predicted move −35% to +45%, predicted peak 0% to +55% around 2026-10 — priority score 8, formula_version 1.0.0. The bands are dominated by sibling catalysts, not by this program; the score’s own gate and the contaminated attribution are why it is nearly the formula’s floor.
• Settles on — Ultragenyx publicly reporting the 64-week results of the Phase 3 Enh3ance study (NCT05345171). Positive means the company’s topline release states that the second primary endpoint, complete responder rate at the final study visit after DTX301 exposure through 64 weeks, was met or achieved, or reports a complete responder rate that it characterises as supporting a regulatory filing. Miss means the release reports the endpoint as not met, reports a complete responder rate without characterising it as supportive of a filing, or the readout is abandoned. Primary source: the Ultragenyx press release and the ClinicalTrials.gov record for NCT05345171.
• Locked: yes · Settled: no

Program data-quality flags

• Open Targets search_entities was BLOCKED for this entire session. Four attempts — two immediate, two spaced minutes apart across the session — all returned the verbatim Rate limit exceeded for client: global, the standing platform throttle documented in 02-connectors.md. The previous sweep (2026-08-05) succeeded on its fourth attempt; this one did not, which is consistent with an intermittent shared throttle rather than a permission gate. The gene–disease corroboration is cited from the previous sweep and tagged as such.
• The BPIQ note field no longer carries its dated changelog. At the 2026-08-05 sweep the field for id 17190 held multiple dated entries; on 2026-08-12 it holds only the newest (“08/04/26:- Enh3ance Ph3 64-week treatment-burden endpoint data expected H1 2027”). The date-slip sequence in Readout therefore carries its first two rows from the previous sweep’s verified reading. A slip count parsed from today’s field alone would silently under-count.
• There is still no peer-reviewed publication of DTX301 human data. According to PubMed, the name-keyed search returns two records (DOI 10.1016/j.omtm.2022.01.007, macaque; DOI 10.1007/s11011-026-01812-0, disease review with two Ultragenyx co-authors) and neither reports Phase 1/2 or Phase 3 clinical results. The previous sweep’s nine-record count came from broader disease-level queries; the finding is identical. Everything known about this drug in people comes from company press releases.
• The previous version of this analysis wrongly reported that DTX301 carries no Fast Track designation. The company’s own “About DTX301” boilerplate in the 2026-03-12 release states Fast Track designation in the United States. Corrected in A.3d this version; the designation is sponsor-stated, with no FDA-side confirmation pulled.
• The 64-week endpoint has no published success threshold. ClinicalTrials.gov names the endpoint (“Complete Responder Rate at the Final Study Visit After DTX301 Exposure”) and gives no definition, no bar and no statistical plan. The definition of “complete responder” used throughout this document — off both scavengers and protein restriction with normal ammonia — is the one Ultragenyx has used consistently in this program and is [UNVERIFIED] as to its exact protocol wording.
• The catalyst date disagrees between sources and is reported rather than reconciled. Company guidance H1 2027 (three dated statements) against a ClinicalTrials.gov primary completion of 2027-09, with the rule 34 modelled estimate (2027-11 to 2028-01) landing wholly after the guided half. Recorded as UNRESOLVED in the Readout block per rule 24.
• After Week 36 the trial loses its contemporaneous control. Eligible placebo patients cross over to DTX301 between Week 36 and Week 64, and the registry describes the second primary endpoint as measured “after DTX301 exposure”. The Week 64 complete-responder analysis is therefore a single-arm proportion, not a randomised comparison.
• The Week 36 efficacy figures come from the company’s own release, not from the registry or a publication. has_results is false on NCT05345171. The 18% reduction, the p=0.018, the 8-of-9 normalisation, the −27% scavenger and +13% protein figures, the Patient Global Impression percentages and the safety summary were all read from the 2026-03-12 release (re-read via a StockTitan rendering this session after the GlobeNewswire page timed out). A sponsor’s own statement, not peer reviewed or independently audited; that is the limit of the check.
• The Patient Global Impression figures rest on different denominators in the same release — 15 patients reporting on overall OTC symptoms, 30 on symptoms and daily-living impact, out of 37 randomised. The release does not explain the difference. The percentages are reported with their denominators rather than presented as if they covered the trial.
• ClinicalTrials.gov discloses no investigator names for NCT05345171. No overall officials, no site contacts — the reason the A.5b investigator table is empty over a fully-enrolled pivotal trial. The KOL panel judgement is UNKNOWN for this reason and for the absence of any independent voice on the endpoint.
• ChEMBL returns no selectivity data, and cannot. CHEMBL4650252 is typed molecule_type “Gene” with structure_type “NONE”: no SMILES, no molecular properties, no bioactivity. The call confirms molecular identity and USAN status (avalotcagene ontaparvovec, 2020) and says nothing about off-target effects. Its max_phase of 1 remains stale against a completed Phase 3.
• The royalty rate on the REGENXBIO AAV8 vector licence could not be confirmed in this sweep either. The licence structure is verified — exclusive worldwide with rights to sublicense, originally granted to Dimension Therapeutics in 2015, fees, milestones and royalties on net sales — and no rate is asserted.
• Anti-AAV8 seroprevalence, which gates eligibility, was not quantified. The protocol excludes patients with detectable pre-existing antibodies to the AAV8 capsid. What fraction of the late-onset OTCD population that removes is [UNVERIFIED] and it is a direct multiplier on every market figure in B.2 and B.3.
• Every peak-sales figure in B.3a is modelled and every input is unverified. No third-party peak-sales forecast specific to DTX301 was found in either sweep. The aggregator figures for the “OTC deficiency treatment market” are recorded in B.3a and explicitly not used as inputs, per rule 6.
• Analyst-target dispersion is extreme and partly stale. Aggregators show consensus targets of $85–94 with a $34–$140 range [WEB ESTIMATE — stockanalysis.com and MarketScreener, read 2026-08-12], but the top of that range predates the 2025-12-29 setrusumab failure, while the freshest post-Q2 actions are far lower (Guggenheim $35, 2026-08-04; Wells Fargo $45, 2026-08-05). No aggregate target is used anywhere in this analysis.
• The committed price cache lags the quote by five trading days. data/prices/RARE.json ends 2026-08-05 ($24.93); the BPIQ quote read 2026-08-12 is $26.67 (previous close $26.96). Both are recorded with their own dates; the run-up entry uses the fresher quote and the exit resolves later against the cache. No price fetch was run in this analysis, per 02-connectors.md.